Related Experiment Videos
[Amyloidosis associated with long-term dialysis]
F Gejyo1, H Maruyama, M Arakawa
1Department of Internal Medicine, Niigata University School of Medicine, Japan.
Nihon Jinzo Gakkai Shi
|January 1, 1995
Summary
Dialysis amyloidosis, caused by beta 2-microglobulin (beta 2-m) buildup in long-term hemodialysis patients, involves cellular uptake of beta 2-m. Current treatments for this complication are limited, though corticosteroids show some efficacy for arthropathy.
Area of Science:
- Nephrology
- Biochemistry
- Pathology
Context:
- Dialysis amyloidosis is a common complication in patients undergoing long-term hemodialysis.
- Amyloid deposits are primarily composed of beta 2-microglobulin (beta 2-m), a protein retained due to impaired kidney function.
- Other substances like amyloid P component, calcium, and various proteins are also found in these deposits.
Purpose:
- To investigate the role of beta 2-microglobulin (beta 2-m) in the pathogenesis of dialysis amyloidosis.
- To explore the uptake of radiolabeled beta 2-m by cells in synovial tissue.
- To review current treatment strategies for beta 2-m-related amyloidosis.
Summary:
- Beta 2-microglobulin (beta 2-m) retention is considered a fundamental requirement for initiating dialysis amyloidosis.
- In vivo studies show radiolabeled beta 2-m accumulates at amyloid deposit sites, with autoradiography confirming cellular uptake in synovial tissue.
- The exact pathogenesis is likely multifactorial, involving beta 2-m and other identified substances.
Impact:
- Understanding beta 2-m accumulation mechanisms can inform future therapeutic strategies for dialysis amyloidosis.
- Corticosteroids may alleviate articular symptoms associated with beta 2-m amyloidosis, but their use requires careful consideration due to potential adverse effects.
- Further research is needed to establish definitive treatments for beta 2-microglobulin-related amyloidosis.